---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-129181"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:15:36.624909+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics awarded $9.5M CPRIT grant for MT-601 in pancreatic cancer study

## Summary
- Received $9.5M non-dilutive grant from CPRIT to support Phase 1 PANACEA study of MT-601 in metastatic pancreatic cancer.
- Also received $2M NIH SBIR grant; total non-dilutive funding exceeds $30M from FDA, NIH, and CPRIT.
- Clinical program initiation for MT-601 in pancreatic cancer expected in 2025.
- Preliminary data from prior multiTAA-specific T cell study showed 1 CR, 3 PRs, 6 SD in 13 pancreatic cancer patients.

## SEC filing metadata
- accession: 0001104659-24-129181
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465924129181/0001104659-24-129181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465924129181/tm2431191d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-129181
- JSON: https://secwatch.observer/filing/0001104659-24-129181.json
- Plain text: https://secwatch.observer/filing/0001104659-24-129181.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.